American Heart Association EMS Survey Uncovers Deficiencies in Response, Treatment and Transfer of Patients With Most Deadly Hea... (eir state or region and share it with co...)

HOME >> MEDICINE >> TECHNOLOGY

American Heart Association EMS Survey Uncovers Deficiencies in Response, Treatment and Transfer of Patients With Most Deadly Heart Attacks

Date:2/16/2009

eir state or region and share it with coalitions composed of EMS and hospital personnel, physicians and nurses and health policy makers. The coalitions will use the information to create appropriate plans to improve the care of STEMI patients.

"EMS systems are the point of entry for all heart attack patients and are extremely important to reducing delays to STEMI care," said Alice K. Jacobs, M.D., former president of the American Heart Association and chair of the Mission: Lifeline advisory working group. "Our survey provides the American Heart Association and its coalition partners a great snapshot of their local EMS and where we need to make progress. It confirms the need for better coordination between EMS, emergency departments and hospitals in order to do what's best for the patient."

Other findings include:

More paramedics should receive training on interpreting 12 lead ECGs.
Funding is needed for additional 12 lead ECG devices and training.
Information sharing between EMS and hospitals is poor, so it's difficult to track the quality of care a patient receives as they move from EMS to hospital-based care. Confidentiality requirements are hindering the process.

The need for Mission: Lifeline

Each year, about 400,000 people in the U.S. have a type of heart attack known as STEMI, in which blood flow is completely blocked to a portion of the heart. Unless the blockage is eliminated quickly, the patient's health and life are at serious risk. The American Heart Association recommends that STEMI patients receive PCI procedures like angioplasty to restore blood flow to the heart muscle within 90 minutes. The association created Mission: Lifeline to close the gaps that separate STEMI patients from timely access to appropriate treatment. For more information ab
'/>"/>

SOURCE American Heart Association
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
4. Aspirin Named 8th World Wonder by Majority of Americans
5. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
6. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
7. TrialCheck(R) Cancer Clinical Trial Matching Interface to Debut on American Cancer Society Web Site
8. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
9. Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
10. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
11. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting

Post Your Comments:

(Date:5/23/2013)... , May 23, 2013 Isis Pharmaceuticals, Inc. ... today announced that management will present a company overview at ... Conference on Thursday, May 30, 2013 at 8:40 a.m. ET ... live audio webcast of the presentation will be available on ... www.isispharm.com . A replay will be available on the ...

(Date:5/23/2013)... TUCSON, Ariz. , May 23, 2013 ... world,s first and only FDA, Health Canada and CE ... announced today that the Glasgow Science Centre in ... visitors annually, is featuring the SynCardia temporary Total ... as part of its $3 million Bodyworks Exhibition, one ...

(Date:5/23/2013)... , May 23, 2013 BioLife Solutions , ... proprietary clinical grade hypothermic storage and ... contract aseptic media manufacturer , today announced its ... Regenerative Medicine Congress 2013 this week in ... ) Dr. Aby J. Mathew, BioLife,s Senior ...

Breaking Medicine Technology:Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference 2 Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 2 Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 3 BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 2 BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 3

[0] Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference [0] Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition [0] BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress

... - Results Highlight the Potential of ... Algeta ASA (OSE: ALGETA), the ... BC1-04 study reported today it has completed its,comprehensive phase ... for bone metastases in patients with hormone-refractory,prostate cancer (HRPC). ...

... After eight weeks of treatment, RAD001 halted tumor growth ... with chemotherapy - Based on these promising data, Novartis ... advanced gastric cancer patients- Gastric cancer is the second ... of new cases occurring in East AsiaEAST HANOVER, N.J., ...

Cached Medicine Technology:Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer 2 Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer 3 Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer 4 Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer 5 Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer 6 RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 2 RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 3 RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 4 RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 5 RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 6

Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments

(Date:5/23/2013)... high-risk neuroblastoma a common tumor that forms in the ... drugs. A study published by Cell Press in the ... reveals a new genomic approach to screen for compounds ... to differentiate, or convert from immature cells to more ... identified a compound that causes neuroblastoma cells to differentiate, ...

(Date:5/23/2013)... 2013 Sika Sarnafil , the ... today announced Imperial Roof Systems of Iowa as the ... dedication to quality during the re-roofing of the SuperTarget ... a Sika Sarnafil Elite contractor and one of Target’s ... is committed to sustainable building practices and they are ...

(Date:5/23/2013)... 23, 2013 Diabetes is one of ... become a nuisance when patients are unfortunate enough to ... the National Diabetes Information Clearinghouse at http://goo.gl/QyhCz , ... risk of developing neuropathy which further shrivels the nervous ... such patients. Such nerve damage affects the whole body ...

(Date:5/23/2013)... May 23, 2013 Professional Insurance Plans, ... the nation to celebrate Fibromyalgia Education and Awareness Month. ... chiropractors across the country, the agency feels that it ... of this syndrome that affects an estimated 10 million ... Association , the definition of Fibromyalgia (FM) is, “a ...

(Date:5/23/2013)... 2013 Retül University , the ... announce the formation of a strategic educational partnership with ... to offer a bike industry first “Positioned for Speed” ... for time trial, road and triathlon bike fit. , ... bike fitters with a Retül University, F.I.S.T. or S.I.C.I ...

Breaking Medicine News(10 mins):Health News:New screening approach uncovers potential alternative drug therapies for neuroblastoma 2 Health News:Sika Sarnafil Announces Recycling Project of the Year Winner 2 Health News:Neuropathy Nerve Damage Can Now Be Reversed With Neuracel 2 Health News:Professional Insurance Plans Encourages the Nation to Celebrate Fibromyalgia Education and Awareness Month 2 Health News:Retül, Ero Sports and Alphamantis Partner for Industry First Aero Fit Course 2 Health News:Retül, Ero Sports and Alphamantis Partner for Industry First Aero Fit Course 3

[0] New screening approach uncovers potential alternative drug therapies for neuroblastoma [0] Sika Sarnafil Announces Recycling Project of the Year Winner [0] Neuropathy Nerve Damage Can Now Be Reversed With Neuracel [0] Professional Insurance Plans Encourages the Nation to Celebrate Fibromyalgia Education and Awareness Month [0] Retül, Ero Sports and Alphamantis Partner for Industry First Aero Fit Course

... Mark,s Breathe Easy Tour, Inspires Those with Chronic Lung Disease to ... ... SAN DIEGO, July 24 SeQual Technologies Inc. (SeQual),announced today the ... the American Lung,Association of California and Seton Medical Center intended to ...

... PALO ALTO, Calif., July 24 Horizon Therapeutics, ... Timothy P.,Walbert has been named president, chief executive ... Horizon Therapeutics., "Tim has a long, proven ... the pain and arthritis areas," said George,Tidmarsh, M.D., ...

... Free Diabetes Education and Cholesterol ... Screenings to Race Spectators, INDIANAPOLIS, Ind., July ... and Polymer Technology Systems,Inc. as a partner in the recently announced ... as cholesterol,screenings at the IndyCar Series during the 2008 racing season., ...

... $0.51 from $0.38 in ... - Record diluted EPS increased 30.2 percent to $0.56 from $0.43 in, second-quarter 2007, excluding ... from the ... - Specialty revenues increased 32.6 percent to a record of nearly $2.0 ...

... Mass., July 24 Tepha, Inc., a developer ... resorbable polymers, announced,today that it has appointed John ... and Chief Operating Officer. Mr. Hartnett joins Tepha,following ... which he,progressed from field sales, to marketing management, ...

... BEIJING, July 24 /Xinhua-PRNewswire-FirstCall/ -- China Medical,Technologies, ... a leading China-based,medical device company that develops, ... high intensity focused ultrasound tumor,therapy systems, today ... results for the first quarter ended June ...

SeQual Technologies, American Lung Association of California and Seton Medical Center Partner to Support Survivor & Cyclist in 500-Mile California Ride Horizon Therapeutics Names Timothy P. Walbert as President and CEO Eli Lilly and Company and Vision Racing Sponsor Vision Wellness Tour at the IndyCar Series Across the Country Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance Tepha Announces Appointment of John Hartnett as Executive Vice President and Chief Operating Officer China Medical Technologies to Announce Financial Results for the First Quarter Ended June 30, 2008 on August 4, 2008

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

Medicine Products:

Morphine Quantitation, Serum or Plasma Monoethylglycinerylidide, Urine Moricizine (Ethmozine), Serum or Plasma Mono/Dizygotic Differentiation